Zhaoke Acquires China Rights to Myopia Treatment in $102 Million Agreement

Zhaoke ( Hong Kong ) Ophthalmology Pharma acquired Greater China rights to a myopia treatment from Nevakar in a $102 million agreement. NVK-002 is a novel topical treatment aimed at slowing the progression of myopia in children. It is currently being tested in a US-EU Phase III clinical trial. ZKO's parent, Zhaoke Ophthalmology, raised $50 million in a Series A last year and closed a $145 million Series B recently. Zhaoke is described as an indirect non-wholly-owned subsidiary of China in-licensing company Lee's Pharm. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.